Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Healthcare: A Surprising Reversal for Alkermes, Celldex's Super Bad News, and J&J's Q1 in Review

  • Broadcast in Finance
Industry Focus

Industry Focus

Featured Host
×  

Follow This Show

If you liked this show, you should follow Industry Focus.
h:899941
s:10732145
archived
Play
  • Host

Alkermes’ ALKS-5461 gets a do-over, Celldex's lead drug is a bust, and the good and bad of Johnson & Johnson's Q1 earnings report. 

Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code fool.

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled